An uncontrolled study of eight individuals with HNF1A-diabetes assessed the success of transitioning from insulin that had been used since diabetes diagnosis (median insulin dose 0.5 units per kg; median duration of insulin treatment 20 years) to SU (gliclazide, median dose 80 mg daily)29 (Table 5). The gene discussed is INS; the disease is diabetes mellitus.